At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BFRI Biofrontera Inc
Post-Market Trading 11-29 15:39:58 EST
0.9007
-0.0893
-9.02%
盘后0.8834
-0.0173-1.92%
15:38 EST
High0.9700
Low0.8500
Vol449.50K
Open0.9520
D1 Closing0.9900
Amplitude12.12%
Mkt Cap6.98M
Tradable Cap4.72M
Total Shares7.75M
T/O403.61K
T/O Rate8.58%
Tradable Shares5.24M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Benchmark Co. Sticks to Their Buy Rating for Biofrontera (BFRI)
Biofrontera Inc. Announces Highly Significant Results in Phase 3 Study of Ameluz®-Photodynamic Therapy (Pdt) Regarding the Treatment of Superficial Basal Cell Carcinoma (Sbcc)
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.